T2DM With NAFLD Clinical Trial
Official title:
Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease
| Verified date | March 2021 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose study conducted at a single site. The study plans to include up to approximately 46 evaluable subjects with Type 2 Diabetes Mellitus (HbA1c 7-11%) and Non-Alcoholic Fatty Liver disease (liver fat content > = 8%) on metformin monotherapy. Three initial cohorts are planned: - Cohort 1: 6 subjects receiving AZD4076 and 4 subjects receiving placebo - Cohort 2: 12 subjects receiving AZD4076 and 10 subjects receiving placebo - Cohort 3: 10 subjects receiving AZD4076 and 10 subjects receiving placebo, with the possibility to add additional subjects if drop-out rates are higher than expected Pending review by SRC, an additional 2 cohorts, each consisting of 18 evaluable subjects may be included in the study. The primary objectives of this clinical trial are to investigate the safety and tolerability of AZD4076 following subcutaneous administration of multiple ascending doses; to assess the effect of AZD4076 on whole body insulin sensitivity using hyperinsulinemic euglycemic clamp with tracer technique; and to assess the effect of AZD4076 on liver fat content using magnetic resonance imaging. Secondary objectives of this trial are to characterize multiple dose PK of AZD4076 and its longmer and shortmer metabolites and assess the time required to reach steady state and the degree of accumulation; to assess the efficacy of AZD4076 on 24-hour glucose; and to assess the effect of AZD4076 on homeostatic model assessment insulin resistant (HOMA-IR) and Matsuda index.
| Status | Completed |
| Enrollment | 14 |
| Est. completion date | October 11, 2019 |
| Est. primary completion date | October 11, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility | Inclusion criteria 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Males or females of non-child bearing potential. 3. Age 18-70 years with suitable veins for cannulation or repeated venipuncture. 4. BMI 23-40 kg/m2 inclusive. 5. Diagnosed T2D (HbA1c 7-11%) treated with a stable dose of metformin for at least one month prior to screening. 6. Hepatic steatosis of =8%. Exclusion criteria 1. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP. 2. History or presence of hepatic or renal disease (with the exception of hepatic steatosis). 3. Presence of acute proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy. 4. Clinically significant cardiovascular event within the last 6 months prior to screening. 5. History or presence of significant neurological or psychiatric disease/mental illness (as assessed using the C-SSRS). 6. History of malignancy within the last 5 years, excluding successful treatment of basal cell skin carcinoma or in situ carcinoma of cervix. 7. Suspicion of or known Gilbert's syndrome. 8. Supine systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg confirmed in the screening period. 9. Changes in any current medication (initiation, dose change or cessation) that may impact the study readouts (as judged by the Investigator) within three months prior to MRI assessment of steatosis screening. The criterion does not apply to medication prescribed for occasional use. 10 Treatment with antidiabetics (except for metformin) during the last three months prior to screening or treatment with sulfonylurea (SU) drugs within the 4 weeks prior to screening. 11. Used or plan to use drugs that cause weight loss, participating in, or have participated in weight loss program within the last 3 months. 12. Use of anabolic steroids and systemic treatment with glucosteroids within three months prior to screening. Intra articular, topical, and inhaled steroids are permissible. 13. Any confirmed clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the Investigator. 14. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV). 15. Confirmed serum creatinine greater than the ULN. 16. A confirmed eGFR <60 calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 17. Confirmed platelet count outside the normal range. 18. Confirmed ALT or AST greater than 1.5x ULN. 19. Confirmed total bilirubin greater than ULN 20. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead, or left ventricular hypertrophy. 21. Prolonged QTcF > 450 ms for males and > 470 ms for females or family history of long QT syndrome. 22. PR(PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation. 23. PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree AV block, or AV dissociation. 24. Persistent or intermittent complete bundle branch block (BBB) with QRS > 120 ms. 25. Known or suspected history of drug abuse within the past 5 years, as judged by the Investigator. 26. Smokes >10 cigarettes/day and unable to comply with the nicotine restriction during the study. 27. History of alcohol abuse or excessive intake of alcohol. Definition of excessive intake: an average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits. 28. Positive screen for drugs of abuse at screening or admission to the unit or positive screen for alcohol at screening or on admission to the unit prior to the first administration of IMP. 29. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4076. 30. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea), as judged by the Investigator. 31. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP. 32. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 56 days prior to screening. 33. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within one month of the administration of IMP in this study. The period of exclusion begins one month after the final dose or one month after the last visit whichever is the longest. 34. Use of implants or devices that are incompatible with the MRI procedure. 35. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order. 36. Involvement of any Astra Zeneca, PROFIL INSTITUTE or study site employee or their close relatives. 37. Judgment by the Investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements. 38. Subjects not willing to comply with the dietary requirements in the study as judged by the Investigator. 39. Subjects who cannot communicate reliably with the Investigator or designee. 40. Previous bone marrow transplant. 41. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The safety and tolerability of AZD4076 by assessing the number of participants with adverse events | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessment of blood pressure | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessment of pulse | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessment of oral temperature | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From day -2 until day 42 | |
| Primary | The safety and tolerability of AZD4076 by assessment of electrocardiogram readings | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readings | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From predose until 24 hours post-dose on days 1 and 42 | |
| Primary | The safety and tolerability AZD4076 by assessment of physical examination | Percentage of patients with abnormal physical examination | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessing the injection site | Percentage of patients with dermatological adverse events | From day 1 until day 42 | |
| Primary | The safety and tolerability of AZD4076 by assessing the number of adverse events | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessing hematology | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessing clinical chemistry | Percentage of patients with clinically significant changes in laboratory tests. | From screening until 26 weeks post first dose | |
| Primary | The safety and tolerability of AZD4076 by assessing urinalysis | To assess the safety and tolerability of multiple ascending doses of AZD4076 | From screening until 26 weeks post-first dose | |
| Primary | Glucose infusion rate at hyperinsulinemic clamp | To assess the effect of AZD4076 on whole body insulin sensitivity using hyperinsulinemic euglycemic clamp with tracer technique | Day -1 and 56 days post first dose | |
| Primary | Reduction in liver fat content (%) per MRI | To assess the effect of AZD4076 on liver fat content using magnetic resonance imaging | Screening and 54 days post first dose | |
| Secondary | 24 hour glucose area under the curve | To assess the effect of AZD4076 on 24-hour glucose. | Day -2 and day 55 | |
| Secondary | HOMA-IR | To assess the effect of AZD4076 on homeostatic model assessment insulin resistant (HOMA-IR) | Day -2 and day 55 | |
| Secondary | Fasting Endogenous Glucose Production | To assess the effect of AZD4076 on endogenous glucose production (EGP). | Day -1 and day 56 | |
| Secondary | AUCt of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by area under the curve to time | Dosing day 1 and day 42 | |
| Secondary | Matsuda Index | To assess the effect of AZD4076 on Matusda Index | Day -2 and day 55 | |
| Secondary | AUC0-24 of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by area under the curve to 24 hours | Dosing day 1 and day 42 | |
| Secondary | Cmax of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by peak concentration | Dosing day 1 and day 42 | |
| Secondary | Tmax of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by time to peak concentration | Dosing day 1 and day 42 | |
| Secondary | CLR of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by clearance | Day 1 and 42 | |
| Secondary | fe% of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by fraction excreted in urine | Dosing day 1 and day 42 | |
| Secondary | Ae of AZD4076 and longmer and shortmer metabolites | To characterize pharmacokinetics of AZD4076 by amount excreted in urine | Dosing day 1 and day 42 |